Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
RARE | US
-1.76
-3.17%
Healthcare
Biotechnology
30/06/2024
04/10/2024
53.79
53.67
54.50
53.21
Ultragenyx Pharmaceutical Inc. a biopharmaceutical company focuses on the identification acquisition development and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America Latin America Japan Europe and internationally. Its biologic products include Crysvita (burosumab) an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia as well as tumor-induced osteomalacia; Mepsevii an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401 an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301 an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143 a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102 an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102) an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A or MPS IIIA a rare lysosomal storage disease; UX701 for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co. Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co. Ltd. The company was incorporated in 2010 and is headquartered in Novato California.
View LessLow Market Beta (-0.4 to 0.8)
Strong Revenue Growth (> 10%)
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
Midcap (2B - 10B USD)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
27.8%1 month
27.0%3 months
41.6%6 months
45.4%-
-
11.60
2.14
0.57
-6.46
8.91
-0.24
-515.74M
4.96B
4.96B
-
-79.14
-
35.70
-208.43
5.69
4.50
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
6.29
Range1M
7.16
Range3M
20.73
Rel. volume
1.29
Price X volume
41.90M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Krystal Biotech Inc | KRYS | Biotechnology | 177.11 | 5.09B | -0.15% | 44.85 | 0.92% |
Alkermes plc | ALKS | Biotechnology | 28.97 | 4.77B | -0.10% | 12.07 | 28.66% |
Corcept Therapeutics Incorporated | CORT | Biotechnology | 45.43 | 4.75B | -0.94% | 38.88 | 0.95% |
BridgeBio Pharma Inc | BBIO | Biotechnology | 25.23 | 4.74B | 0.60% | n/a | -158.23% |
ADMA Biologics Inc | ADMA | Biotechnology | 20.29 | 4.73B | 4.05% | 138.46 | 75.10% |
Madrigal Pharmaceuticals Inc | MDGL | Biotechnology | 208.41 | 4.53B | -0.35% | n/a | 13.77% |
Common Stock | IMVT | Biotechnology | 30.51 | 4.51B | 3.35% | n/a | 0.01% |
Biohaven Pharmaceutical Holding Company Ltd | BHVN | Biotechnology | 47.63 | 4.50B | -0.75% | n/a | 7.75% |
Crinetics Pharmaceuticals Inc | CRNX | Biotechnology | 53.14 | 4.25B | -1.63% | n/a | 6.42% |
Arcellx Inc. Common Stock | ACLX | Biotechnology | 78.23 | 4.21B | 2.62% | n/a | 15.25% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Polaris Industries Inc | PII | Recreational Vehicles | 82.25 | 4.59B | 0.61% | 14.90 | 170.51% |
Harley-Davidson Inc | HOG | Recreational Vehicles | 34.78 | 4.58B | -4.61% | 7.97 | 218.58% |
BRP Inc | DOOO | Recreational Vehicles | 59.31 | 4.30B | 2.21% | 24.84 | 552.13% |
LCI Industries | LCII | Recreational Vehicles | 118.67 | 3.02B | -1.21% | 25.17 | 77.66% |
VeriFone Systems Inc | PAY | Building Products & Equipment | 20.8 | 2.59B | 4.58% | 76.96 | 2.10% |
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -6.46 | 0.76 | Cheaper |
Ent. to Revenue | 8.91 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 11.60 | 14.10 | Par |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 41.65 | 74.67 | Lower Risk |
Debt to Equity | 2.14 | -1.82 | Expensive |
Debt to Assets | 0.57 | 0.26 | Expensive |
Market Cap | 4.96B | 3.73B | Market Leader |